Skip to Content

ApoGen Receives $7 Million Investment for Cancer Therapy

Researcher with pipettes and petri dishes

A University of Minnesota startup recently attracted a major investment to support continued development of drug therapies that make cancer treatments more effective.

ApoGen Biotechnologies Inc., launched in October 2014, announced last month that it had received $7 million from life science investment firm Accelerator Corporation to continue developing a new class of drugs that slows the evolution of cancer cells and to move these treatments toward clinical trials. ApoGen is based on discoveries by two U researchers: Reuben Harris, Ph.D., professor of biochemistry, molecular biology and biophysics; and Daniel Harki, Ph.D., assistant professor of medicinal chemistry. John Santini Jr., Ph.D., is the company’s president and CEO.

Cancer therapies often become less effective over time as cancer cells become resistant to treatment. ApoGen’s drugs are designed to block a key enzyme that causes drug resistance, potentially making current and future treatments more effective.

“I have been working with Drs. Harris and Harki to move ApoGen’s science toward clinical and commercial development, and I am thrilled to now partner with Accelerator Corporation,” Santini said in a press release. “We believe that we have assembled the ideal team to advance our therapeutic technologies to slow or stop tumor evolution, which has the potential to yield a significant clinical impact for cancer patients.”

Russ Straate, associate director of the Venture Center, part of the U’s Office for Technology Commercialization, said Accelerator Corporation’s investment marks a milestone for ApoGen.

“For a startup that aims to develop a therapy based on innovative research and bring it to market, an investment like this is crucial,” Straate said. “This funding will help ApoGen in its next steps toward clinical trials and move it closer to the ultimate goal of getting this unique cancer therapy into the hands of those who can benefit from it.”

For more on the Accelerator Corporation’s investment in ApoGen, see the College of Biological Sciences blog.

Kevin Coss

Kevin Coss

Kevin is a writer and public relations associate with the Office of the Vice President for Research.

coss@umn.edu

Latest Blog Posts

Palace of Nations in Geneva, Switzerland

Researchers in the U's Center on Women, Gender, and Public Policy recently traveled to the United Nations Human Rights Council in Geneva to persuade its members to pressure Colombia to address an epidemic of violence against women.

Read More
Johnston Hall name covered by ivy

The Minnesota Futures Grant Program is offered annually by the Office of the Vice President for Research to promote research that incorporates new, cross-disciplinary ideas. The most recent cycle saw 35 submissions, with two proposals awarded a total of $499,367.

Read More
Robert Vince is honored onstage for his National Academy of Inventors Fellowship

Robert Vince Ph.D., inventor of the AIDS drug Ziagen and one of the University of Minnesota's most prolific researchers, was recently honored at the National Academy of Inventors 2018 Annual Conference as an NAI Fellow.

Read More
Minneapolis mayor Jacob Frey speaks at gBETA startup event

Accelerators, like gener8tor's gBETA and gBETA Medtech, help startups connect with mentors, investors, and customers to set the stage for future growth.

Read More